Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Buy at StockNews.com

StockNews.com cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from a strong-buy rating to a buy rating in a report issued on Saturday.

Separately, Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

SUPN stock traded down $0.82 during trading on Friday, reaching $32.02. 1,315,129 shares of the company were exchanged, compared to its average volume of 543,403. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.83. The company has a 50-day moving average of $36.62 and a two-hundred day moving average of $35.27.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $42,000. Smartleaf Asset Management LLC boosted its stake in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in Supernus Pharmaceuticals in the fourth quarter worth $52,000. Finally, Headlands Technologies LLC increased its stake in Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.